Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses

被引：4
|
作者：
Ring, Sandra S. [1 ]
Krolik, Michal [1 ]
Hartmann, Fabienne [1 ]
Schmidt, Erika [3 ]
Ali, Omar Hasan [1 ,2 ]
Ludewig, Burkhard [1 ,2 ]
Kochanek, Stefan [3 ]
Flatz, Lukas [1 ,4 ,5 ,6 ]
机构：
[1] Kantonsspital St Gallen, Inst Immunobiol, Rorschacher Str 95, CH-9007 St Gallen, Switzerland
[2] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland
[3] Ulm Univ, Dept Gene Therapy, Helmholtzstr 8, D-89081 Ulm, Germany
[4] Univ Hosp Zurich, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland
[5] Kantonsspital St Gallen, Dept Oncol & Hematol, Rorschacher Str 95, CH-9007 St Gallen, Switzerland
[6] Kantonsspital St Gallen, Dept Dermatol, Rorschacher Str 95, CH-9007 St Gallen, Switzerland
来源：
MOLECULAR THERAPY-ONCOLYTICS | 2020年 / 19卷
关键词：
ANTIGEN-SPECIFIC CD8(+); METASTATIC MELANOMA; VIRAL VECTORS; VIRUS-INFECTION; DOUBLE-BLIND; CYCLOPHOSPHAMIDE; GENE; CANCER; IMMUNITY; INTERLEUKIN-2;
D O I：
10.1016/j.omto.2020.10.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cancer vaccination aims at inducing an adaptive immune response against tumor-derived antigens. In this study, we utilize recombinant human adenovirus serotype 5 (rAd5) and recombinant lymphocytic choriomeningitis virus (rLCMV)based vectors expressing the melanocyte differentiation antigen gp100. In contrast to single or homologous vaccination, a heterologous prime boost vaccination starting with a rAd5-gp100 prime immunization followed by a rLCMV-gp100 boost injection induces a high magnitude of polyfunctional gp100-specific CD8(+) T cells. Our data indicate that an optimal T cell induction is dependent on the order and interval of the vaccinations. A prophylactic prime boost vaccination with rAd5-and rLCMV-gp100 protects mice from a B16.F10 melanoma challenge. In the therapeutic setting, combination of the vaccination with low-dose cyclophosphamide showed a synergistic effect and significantly delayed tumor growth. Our findings suggest that heterologous viral vector prime boost immunizations can mediate tumor control in a mouse melanoma model.
引用
收藏
页码：179 / 187
页数：9
相关论文
共 50 条
  • [31] Targeting a Mimotope Vaccine to Activating Fcγ Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice
    Gil, Margaret
    Bieniasz, Magdalena
    Wierzbicki, Andrzej
    Bambach, Barbara J.
    Rokita, Hanna
    Kozbor, Danuta
    JOURNAL OF IMMUNOLOGY, 2009, 183 (10) : 6808 - 6818
  • [32] A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria
    Vijayan, Aneesh
    Mejias-Perez, Ernesto
    Espinosa, Diego A.
    Raman, Suresh C.
    Sorzano, Carlos Oscar S.
    Zavala, Fidel
    Esteban, Mariano
    CLINICAL AND VACCINE IMMUNOLOGY, 2017, 24 (05)
  • [33] Nonclassical monocytes potentiate anti-tumoral CD8+ T cell responses in the lungs
    Padgett, Lindsey E.
    Marcovecchio, Paola M.
    Olingy, Claire E.
    Araujo, Daniel J.
    Steel, Kathleen
    Dinh, Huy Q.
    Alimadadi, Ahmad
    Zhu, Yanfang Peipei
    Meyer, Melissa A.
    Kiosses, William B.
    Thomas, Graham D.
    Hedrick, Catherine C.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] Protective Antibody and CD8+ T-Cell Responses to the Plasmodium falciparum Circumsporozoite Protein Induced by a Nanoparticle Vaccine
    Kaba, Stephen A.
    McCoy, Margaret E.
    Doll, Tais A. P. F.
    Brando, Clara
    Guo, Qin
    Dasgupta, Debleena
    Yang, Yongkun
    Mittelholzer, Christian
    Spaccapelo, Roberta
    Crisanti, Andrea
    Burkhard, Peter
    Lanar, David E.
    PLOS ONE, 2012, 7 (10):
  • [35] CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
    Yuan, Jianda
    Ginsberg, Brian
    Page, David
    Li, Yanyun
    Rasalan, Teresa
    Gallardo, Humilidad F.
    Xu, Yinyan
    Adams, Sylvia
    Bhardwaj, Nina
    Busam, Klaus
    Old, Lloyd J.
    Allison, James P.
    Jungbluth, Achim
    Wolchok, Jedd D.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (08) : 1137 - 1146
  • [36] The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity
    Marois, Isabelle
    Cloutier, Alexandre
    Garneau, Emilie
    Lesur, Olivier
    Richter, Martin V.
    FASEB JOURNAL, 2015, 29 (03) : 973 - 987
  • [37] Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma
    Qiu, Zhijuan
    Huang, Huakang
    Grenier, Jeremy M.
    Perez, Oriana A.
    Smilowitz, Henry M.
    Adler, Barbara
    Khanna, Kamal M.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) : 536 - 546
  • [38] Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
    Choi, Joshua
    Meilleur, Courtney E.
    Haeryfar, S. M. Mansour
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2019, (147):
  • [39] Dissecting the Protective Effect of CD8+ T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8+ T Cells
    Chen, Mengfei
    Venturi, Vanessa
    Munier, C. Mee Ling
    BIOLOGY-BASEL, 2023, 12 (07):
  • [40] Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8+ T cell responses
    Bertino, Pietro
    Urschitz, Johann
    Hoffmann, Fukun W.
    You, Bo Ra
    Rose, Aaron H.
    Park, Woo Hyun
    Moisyadi, Stefan
    Hoffmann, Peter R.
    VACCINE, 2014, 32 (15) : 1670 - 1677
12345